Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
CNS Disorders
Advertisement
Praxis Precision Medicines Reports Strong Elsunersen Trial
Boston, Massachusetts, USA, April 6, 2026 Breakthrough Results in Rare Pediatric Epilepsy In a major advancement for precision neuroscience...
Enveric Biosciences Gains U.S. Patent for EVM301
CAMBRIDGE, Mass., March 31, 2026 Enveric Biosciences has strengthened its position in the rapidly evolving neuropsychiatric drug development space...
Praxis Precision Medicines Gains FDA Priority Review Boost
BOSTON, March 30, 2026 Praxis Precision Medicines has achieved a major regulatory milestone as the U.S. Food and Drug...
Lupin Gets FDA Nod for Pitolisant Tablets
MUMBAI, INDIA & NAPLES, USA | March 25, 2026 Lupin Limited, a global pharmaceutical leader, has received tentative approval...
Advertisements
Jupiter Neurosciences Aligns Capital With Clinical Growth
JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...
Alkermes Expands Sleep Portfolio With Avadel Buy
DUBLIN, Feb. 12, 2026 — Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, accelerating its strategic entry...
IRLAB and Biomia Partner to Advance CNS Drug Discovery
GOTHENBURG, Sweden | January 19, 2026 — IRLAB Therapeutics AB, a clinical-stage company focused on novel treatments for Parkinson’s...
Nxera Reports Positive Phase 3 Results for Daridorexant
TOKYO, Japan and CAMBRIDGE, United Kingdom | January 19, 2026 — Nxera Pharma Co., Ltd. announced positive top-line results...
FDA Reviews New Data to Advance SL1009 for Rare PDCD
ROSWELL, Ga., DUBLIN & HAMILTON, Bermuda — December 9, 2025 — Saol Therapeutics announced that the U.S. Food and...
Advertisement
